Kenzik KM, et al. - A retrospective cohort study was conducted to compare healthcare expenditure correlated to imatinib treatment for individuals with chronic myeloid leukemia (CML) prior to its generic status with expenditures after, in a real-world setting. between September 1, 2014, and December 31, 2017, researchers used data from the Truven Health MarketScan Database including 1,301 commercially insured individuals or individuals with Medicaid between the ages of 18 and 64 years with a CML diagnosis. They applied a single interrupted time series method to estimate monthly expenditures correlated with imatinib for the health plan from September 1, 2014, to December 31, 2017, with imatinib switching to generic on February 1, 2016, as the interruption. A sum of 1,301 individuals were included (1102 commercially insured and 199 insured through Medicaid) with a median (range) age at diagnosis of 50 (18-62) years for commercially insured individuals and 50 (47-52) years for individuals with Medicaid. The results of this study showed that the modest decline in expenditure correlated with imatinib after generic entry followed by the increasing expenditure trends connected with the second-generation tyrosine kinase inhibitors implies a requirement for measures to facilitate cost reduction as well as standardization of CML treatment.